Resultados Chilenos del registro internacional de factores de riesgo y tratamiento de angina inestable e infarto al miocardio sin supradesnivel del segmento ST: ACCORD (ACute CORonary syndrome Descriptive study)

Stockins, B; Albornoz, Francisco; Martínez, Darío; Campos, Pabla; Gajardo, Jorge; Lamich, Rubén; Manríquez, Leopoldo; Pérez, Víctor; Rojo, Pamela; Sepúlveda, Pablo; Pumarino, M. Gabriela; Corbalán, Ramón

doi:10.4067/s0034-98872011000100003

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies were conducted in Brazil [ 3 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 ]. Six studies were conducted in Argentina [ 59 60 61 62 63 64 ], four in Chile [ 65 66 67 68 ], four in Colombia [ 69 70 71 72 ], three in Uruguay [ 73 74 75 ] and two were multi-country studies conducted in Argentina, Brazil, Chile and Colombia [ 12 ] and Brazil and Suriname [ 76 ]. The most common language of the articles was English (58 articles), followed by Spanish (11 articles) and Portuguese (4 articles).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Cardioprotective Medication Use in Coronary Heart Disease Patients in South America: Systematic review and Meta-Analysis

Marzà-Florensa

Drotos

Gulayin

et al. 2022

View full text Add to dashboard Cite

Background: Coronary heart disease (CHD) is the most common cause of death globally, and clinical guidelines recommend cardioprotective medications for patients with established CHD. Suboptimal use of these medications has been reported, but information from South America is scarce. Methods: We conducted a systematic review on prevalence of secondary prevention medication in South America. We pooled prevalence estimates, analysed time-trends and guideline compliance, and identified factors associated with medication use with meta-regression models. Results: 73 publications were included. Medication prevalence varied by class: beta-blockers 73.4%(95%CI 66.8%–79.1%), ACEI/ARBs 55.8%(95%CI 49.7%–61.8), antiplatelets 84.6%(95%CI 79.6%–88.5%), aspirin 85.1%(95%CI 79.7%–89.3%) and statins 78.9%(95%CI 71.2%–84.9%). The use of beta-blockers, ACEI/ARBs and statins increased since 1993. Ten publications reported low medication use and nine reported adequate use. Medication use was lower in community, public and rehabilitation settings compared to tertiary centres. Conclusion: Cardioprotective medication use has increased, but could be further improved particularly in community settings.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Half of them reported that medication use was low [59,62,[76][77][78] or insufficient compared to guideline recommendations [2,12,48,61,79]. Other articles reported that cardioprotective medication use was adequate or high [32,60,66,67,73,75], or in line with guideline recommendations [38,65,80].…”

Section: Guideline Compliancementioning

confidence: 99%

Prevalence of Cardioprotective Medication Use in Coronary Heart Disease Patients in South America: Systematic review and Meta-Analysis

Marzà-Florensa

Drotos

Gulayin

et al. 2022

View full text Add to dashboard Cite

show abstract

Use of medicines recommended for secondary prevention of acute coronary syndrome

et al. 2015

View full text Add to dashboard Cite

OBJECTIVE : To analyze if the demographic and socioeconomic variables, as well as percutaneous coronary intervention are associated with the use of medicines for secondary prevention of acute coronary syndrome.METHODS : In this cohort study, we included 138 patients with acute coronary syndrome, aged 30 years or more and of both sexes. The data were collected at the time of hospital discharge, and after six and twelve months. The outcome of the study was the simultaneous use of medicines recommended for secondary prevention of acute coronary syndrome: platelet antiaggregant, beta-blockers, statins and angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker. The independent variables were: sex, age, education in years of attending, monthly income in tertiles and percutaneous coronary intervention. We described the prevalence of use of each group of medicines with their 95% confidence intervals, as well as the simultaneous use of the four medicines, in all analyzed periods. In the crude analysis, we verified the outcome with the independent variables for each period through the Chi-square test. The adjusted analysis was carried out using Poisson Regression.RESULTS : More than a third of patients (36.2%; 95%CI 28.2;44.3) had the four medicines prescribed at the same time, at the moment of discharge. We did not observe any differences in the prevalence of use in comparison with the two follow-up periods. The most prescribed class of medicines during discharge was platelet antiaggregant (91.3%). In the crude analysis, the demographic and socioeconomic variables were not associated to the outcome in any of the three periods.CONCLUSIONS : The prevalence of simultaneous use of medicines at discharge and in the follow-ups pointed to the under-utilization of this therapy in clinical practice. Intervention strategies are needed to improve the quality of care given to patients that extend beyond the hospital discharge, a critical point of transition in care.

show abstract

Resultados Chilenos del registro internacional de factores de riesgo y tratamiento de angina inestable e infarto al miocardio sin supradesnivel del segmento ST: ACCORD (ACute CORonary syndrome Descriptive study)

Cited by 2 publications

References 21 publications

Prevalence of Cardioprotective Medication Use in Coronary Heart Disease Patients in South America: Systematic review and Meta-Analysis

Prevalence of Cardioprotective Medication Use in Coronary Heart Disease Patients in South America: Systematic review and Meta-Analysis

Use of medicines recommended for secondary prevention of acute coronary syndrome

Contact Info

Product

Resources

About